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• Introduction-Problem-
Breast cancer is one of the most common and dangerous diseases 
that affects women today. In 1994, approximately 182,000 women were 
diagnosed with breast cancer. (Sondik, 1994) This disease has become the 
most common type of cancer among American women, accounting for more 
than 30% of all cases. (American Cancer Society, 1994; Sondik, 1994) The 
fact that the number of new cases each year has been gradually increasing 
throughout much of the last decade is very ominous. (Sondik, 1994) From 
1970 to 1990, the incidence of breast cancer in the United States 
• increased over 21 %. (Sondik, 1994) (Figs. 1 & 2) 
• 
While the overall mortality rate increased only 3% from 1970 to 
1990, 46,000 women still died of cancer in 1993. (Fig. 1) The only cancer 
more deadly was lung cancer. (American Cancer Society, 1994; Sondik, 
1994) In Iowa alone, 2,200 women died of the disease in 1994. (American 
Cancer Society, 1994) These statistics are reason for great concern. As 
explained by Edward J. Sondik, Ph.D, ·sased on the trends to date, there is 
every reason to believe that the burden . of this disease will continue to 
grow, not only in terms of absolute numbers of cases, but in incidence and 
mortality rates." ( 1994) This opinion of Dr. Sondik, is supported by recent 
1 
• estimates from the National Cancer Institute. The risk that a woman will develop breast cancer in her lifetime in now 1 in 8. (Sondik, 1994) 
The increasing incidence rate, the increasing mortality rate, and the 
sheer numbers of women that live with breast cancer each year make this 
a very real and severe problem to the women of today and tomorrow. 
However, women are not the only ones threatened by breast cancer. 
Approximately 1,000 men are diagnosed with breast cancer each year, and 
approximately 300 die of the disease. (American Cancer Society, 1994) 
All of these factors demand a greater understanding of this life-
threatening condition. Learning more about breast cancer offers the 
• possibility of uncovering new techniques for earlier detection and more 
effective treatment. 
• 
One treatment for breast cancer is mastectomy, or surgical removal 
of the breast tissue. The amount of tissue removed during a mastectomy 
depends on the severity of the cancer. For example, when an isolated 
region of tumor cells is found, most often only that section of the breast 
is removed . This process is known as lumpectomy. A partial or segmental 
mastectomy consists of removing approximately one-quarter of the breast 
tissue. A simple or total mastectomy involves removal of the entire 
breast in which cancer has been found. When cancer has spread from the 
2 
• breast to the underarm lymph nodes and the lining over the chest muscles, 
these tissues must be removed in a procedure known as a modified radical 
mastectomy. A radical mastectomy consists of removing the entire 
breast, the underarm lymph nodes, and the chest muscles underneath the 
breast. 
Some women diagnosed with breast cancer have risk factors that 
increase their chance of developing breast cancer again. There are three 
primary risk factors. The first is a high family history of cancer. For 
example, some patients have a mother, sisters, aunts, or grandmothers 
that either have or have had breast cancer. Other types of cancer, such as 
• prostate, ovarian, and colo-rectal, confer higher risk of recurrence. The 
second risk factor contributing to a high chance of recurrence is age at 
diagnosis. The younger a woman is when she is diagnosed with breast 
cancer, the higher the risk of developing cancer again. The reasons for 
this are many, but most important is the fact that women who are young 
when they are diagnosed with cancer often have a genetic susceptibility 
to breast cancer. Serious tumor grade is the third risk factor. The more 
serious and developed a tumor is, the greater the chance that cancer will 
redevelop after the tumor is treated. 





have a mastectomy to remove the tumor. When a women also has one or 
more of these risk factors, the treatment is often more aggressive. In 
many cases, a prophylactic mastectomy is performed in addition to the 
mastectomy to remove the cancerous tissue. A prophylactic mastectomy 
is the removal of a non-cancerous breast in order to prevent tumor 
development that can spread to other parts of the body. This procedure 
often causes a great deal of emotional suffering to a woman, even when 
the surgery is elective. For this reason, as well as the fact that cancer 
may have never developed in the normal breast, the procedure is quite 
considered quite aggressive. Even so, many prophylactic mastectomies 
are performed each year . 
However, the need for such an aggressive precautionary procedure 
has been questioned. Despite the number of prophylactic mastectomies 
performed, relatively little is known about the genetics of women who 
have had the procedure. For this reason, I conducted a study on the genetic 
material of women who had prophylactic mastectomy surgery at the Mayo 
Clinic in Rochester, Minnesota. This project was part of a larger study 
headed by Lynn Hartmann, M.D. and Robert Jenkins, M.D./Ph.D on the 
clinical, psychosocial, and molecular aspects of women who have had 
prophylactic mastectomies . This thesis documents the severity of cancer 
4 
• in America today, the effect of genetics on the development and progression of cancer, and the results of my study on the genetic 
characteristics of women who have had prophylactic mastectomy surgery. 
Background-
What exactly is cancer? It is a term that is heard every day in the 
news, but the definition is somewhat vague to many. In a nutshell, cancer 
is a condition characterized by uncontrolled cell growth. The American 
Cancer Society defines cancer as, • ... a group of diseases characterized by 
• uncontrolled growth and spread of abnormal cells." (1994) For some 
reason, the cells of the body lose their ability to control their duplication. 
Cell division, is an entirely normal process required for organism 
• 
maintenance and growth. However, when it is uncontrolled, many 
problems develop. Cell reproduction is controlled by a complex network of 
systems that make up the cell cycle. When a part, or parts of this system 
break down, the result is uncontrolled cell replication. Usually, this loss 
of control occurs in a single cell. When this single cell loses control of 
its replication machinery, it keeps dividing and dividing, increasing in 





many copies of the same cell. This loss of cell differentiation is termed 
anaplasia. An abnormal growth made up of a collection of new cells is 
called a neoplasm. When the neoplasm is made up of anaplastic cells, it is 
known as a tumor. 
Tumors are quite complicated and developed biologically. Since 
tumor cells reproduce much faster than normal cells, they soon reach a 
growth limit imposed by their environment, the body. For example, cells 
are supplied with oxygen, glucose, and other nutrients by blood vessels 
known as capillaries. When a concentrated growth of cells develops, as in 
a tumor, the cells exhaust the nutrient supplies the blood vessels can 
bring to that area. To remedy this situation, tumor cells release factors 
that promote blood vessel formation, a process known as angiogenesis. In 
this fashion, a tumor may continue its growth beyond normal limits. 
As the severity of the tumor increases, it begins to branch out, a 
process known as metastasis. Cancer is a metastasizing tumor. A 
cancerous tumor is known as a malignant tumor. A tumor that is not 
cancerous is known as benign . One of the ways a tumor branches out, 
ironically, is by the vessels it helped form. The tumor uses the blood 
vessels it produced to carry tumor cells through the bloodstream to other 
areas of the body . Once established, these tumor cells keep dividing, 
6 
• eventually forming another tumor. These peripheral tumors are known as 
satellite tumors. As a result, by the time a person has cancer, they may 
have a vast network of tumors throughout many portions of their body. 
This is one of the reasons cancer is such a deadly disease -it can affect 
many parts of a person's body. Also, metastasis makes cancer very tough 
to eliminate. Even after a major tumor is removed, other tumors may still 
be present or in the process of developing. This is why early detection is 
integral in a successful fight against cancer; detecting cancer early 
increases the chances of eliminating the tumor cells before they have the 
opportunity to spread. Fortunately, most cancers are detected quite early. 
• (Fig. 8) 
• 
he fact that cancer spreads very easily in the human body and is 
resistant to treatment makes it very serious. Perhaps most threatening 
of is the frequency wiU1 wh ch cancer develops in the United States. The 
high prevalence of breast cancer in American women has already been 
mentioned ; however, those numbers appear minor when compared to the 
estimated 1,208,000 new cancer cases diagnosed in 1994. (American 
Cancer Society, 1994) This figure does not even include minor cancers 
such as in situ carcinomas and basal and squamous cell skin cancers. The 
severity of cancer is strikingly evident in the 538,000 cancer deaths in 
7 
• 1994, amounting to 1400 people each day. (American Cancer Society, 
1994) Alarmingly, one in every five deaths in the .United States today is 
due to cancer. (American Cancer Society, 1994) 
Cancer can be caused by a variety of external or internal factors . 
Examples of external factors are chemicals, radiation, and viruses. 
Internal factors such as hormones, immune conditions, and inherited 
mutations cari also cause the disease. (American Cancer Society, 1994) 
One of the most common is the mutation of genetic material in a tumor 
cell. The genetic material of humans, as well as other organisms, is 
Deoxyribose Nucleic Acid, or DNA. DNA is composed of two strands that 
• form a right-handed double helix, like two spiral staircases · entwined. 
(Fig. 9a) Each strand is composed of many nucleotide bases hooked 
together in a chain pattern, end-to-end. Each nucleotide base is made up 
of three main parts: a sugar, a nucleic acid, and a triphosphate. The sugar 
in DNA is deoxyribose, which is composed of five carbons. The nucleic 
add can be either adenine, cytosine, guanine, or thymine. The phosphate 
group of one nucleotide acts to hold the bases together in strand 
formation by attaching to the sugar of another nucleotide. (Fig. 9a) 
The DNA of each cell is wound around histone proteins, forming 
structures called nucleosomes . These nucleosomes form a substance 
• 8 
• called chromatin, which makes up the basic genetic structures of each 
cell, the chromosomes. (Fig. 9b) Each chromosome has a central po~ion 
called the centromere, which lies about one-third of the distance from one 
of the ends. This centromere divides two regions, called arms, of the 
chromosome. The short arm is referred to as the •pN arm, while the long 
arm is referred to as the Nq" arm. (Fig. 9c) All of the genetic information 
of human cells is contained in 23 chromosomes. (Fig. 9d) Each cell has 
two copies of each of the 23 chromosomes. On each of the 23 different 
chromosomes, there is different information that makes each organism 
unique. The sections of each chromosome that make us unique are known 
• as genes. Genes code for different polypeptides, or proteins. Since there 
are two copies of each chromosome, there are two copies of each gene in 
each cell. Each one of these copies is known as an allele. How many 
copies of each chromosome an organism has determines the phenotype, or 
external characteristics, of an organism . For example, in some cases, 
individuals end up with three copies of chromosome 21, a situation known 
as trisomy-21. Trisomy-21 leads to the condition of Down's Syndrome. 
• 
How does DNA determine who we are? It is based on two cellular 
processes, known as transcription and translation. Each base in the DNA 
making up a chromosome is considered part of a three-base unit known as 
9 
• 
a codon. Each three base unit codes for one amino acid, the base unit of 
protein. Each amino acid is put together to make a substance called 
messenger Ribonucleic Acid, or mRNA. Thus, the DNA is transcribed, or 
copied, into mRNA. During translation, this copied mRNA is used as a 
template to make proteins. As mentioned earlier, each codon from mRNA 
codes for an amino acid; the amino acids are then hooked together via 
connections known as peptide bonds into polymers called polypeptides. In 
other words, polypeptides are just long chains of amino acids. When a 
polypeptide gets long enough, interactions between the amino acids give 
the polypeptide a three-dimensional structure. This three-dimensional 
polypeptide is known as a protein. 
Proteins do many different things in a cell. Possibly their most 
important role is acting as enzymes, which serve as catalysts for 
biological reactions. Catalysts allow reactions to occur much more 
quickly than they would unaided. Proteins also serve as transcription 
factors and many other things. These reactions make the various 
processes of life possible, such as metabolism. Therefore, life is made 
possible by proteins, which owe their properties to the three-dimensional 
structure made possible by the unique sequence of DNA. 





thus, it has slightly different genes. This is what makes us unique . 
However, some DNA, most notably the DNA that codes for proteins, must 
have a set sequence in order to produce viable proteins. If the · sequence is 
lost or incorrect, the correct protein is not produced and the function it 
serves is not fulfilled. In diseases that are genetic, this is the problem. 
Cancer is often a genetic disease. Many types of cancer show genetic 
irregularities in the DNA of the tumor cells. The irregularities are 
amazingly complex; there are many types of changes in each of the 
different cancers. In many cancers, more than one chromosome is altered, 
or parts of many chromosomes may be lost. (Fig. 9d) 
One method of measuring genetic instability, in terms of loss or gain 
of an allele, is termed loss of heterozygosity. If a person has two 
identical copies of a gene, they are termed homozygous for that gene. If a 
person has two slightly different copies of a gene, they are termed 
heterozygous for that gene. In less of heterozygosity, or LOH studies, 
normal DNA is compared to tumor DNA. Only heterozygous DNA may be 
used for this method. This is due to the fact that one of the alleles of the 
tumor DNA is compared to one of the alleles of the normal DNA. By using 
this reference, it is possible to tell if one of the alleles has been lost, as 





it is impossible to notice if there has been loss or gain, for this reason, 
they prefer the term allelic imbalance (Al). (Borg et al., 1994) 
Chromosome deletions have been noted in breast tumor DNA on 
chromosomes 1 p (Genuardi et al., 1989; Bieche et al., 1990), 1 q (Merlo et 
al., 1989), 3p (Ali et al., 1989; Chen et al., 1994), 4p (Dutriallaux et al., 
1990), 6q, Sp, 9p, 11p, 11q, 13q, 16q, 17p, 17q, and 18q. The great number 
of chromosomal deletions makes elucidating the cause of cancer very 
difficult. Adding to this problem is the . difficulty in differentiating the 
chromosomal deletions that caused the cancer and those that evolved later 
on, such as during metastasis. While these factors make cancer research 
very difficult, they are the same reasons cancer research is so necessary . 
If we learn more about one of the chromosomal deletions, it may unlock 
answers to deletions on other chromosomes as well. 
Since the transfer of genetic information from one generation to 
another is by the transmission of chromosomes during meiosis, and there 
are so many chromosomal alterations and deletions in breast cancer, it 
can be hypothesized that a large amount of breast cancer develops because 
of genetic inheritance . This is not the case. In fact, breast cancer is 
predominantly sporadic. Only around 10% of the cases are hereditary. 
(Lindblom et al., 1993) 
12 
• Even though only 10% of all breast cancer cases are inherited, this still amounts to many women inheriting breast cancer each year. A gene 
that causes a cell to take on some of the characteristics of a cancer cell 
is called an oncogene. (Bishop, 1985) Some oncogenes are introduced to 
the cell by viruses, such as the Rous sarcoma virus of chickens, which can 
transfer normal cells to a malignant state. (Stehlin, 1976) However, the 
Rous sarcoma virus was not originally carcinogenic, it became so only 
after "kidnapping" a normal cellular gene. This type of gene was called a 
proto-oncogene by Varmus and Bishop. (Stehlin, 1976). Proto-oncogenes 
become oncogenes - and thus cause malignancy - when activated by 
• something else. What activates proto-oncogenes? Basically, anything in 
the environment that can cause a mutation in the DNA. In fact, the 
carcinogenic potency of chemical compounds is directly correlated with 
their mutagenic ability. (Mccann, 1975) 
• 
Why, if proto-oncogenes can be activated into oncogenes and cause 
cancer, do we have them in our genetic material? After all, about 50 of 
the 50,000-100,000 genes in the human genome are proto-oncogenes. 
(Weinberg, 1994) The answer lies in the .fact that proto-oncogenes encode 
many of the proteins that allow a cell to respond to growth factors. In 
other words, when a cell is informed to reproduce, proto-oncogenes are 
13 
• activated and begin churning out the materials that make cell division and replication possible, or instruct other genes to do so. This is a normal 
part of cell metabolism and the cell cycle. However, when a proto-
oncogene is mutated, and thus activated, they lose their ability to be 
regulated - to be shut on or off by environmental cues - and thus keep 
promoting cellular division. At this point, they are oncogenes. Often, 
activation occurs by chromosome transversion, the switching of two 
chromosome arms. Such a switch sometimes places a proto-oncogene next 
to a promoter, which leads to abnormal and unintended cell growth. 
Robert Weinberg explains the conversion of proto-oncogene into oncogene 
• very well, • ... oncogenes are hyperactivated versions of normal cellular 
• 
growth-promoting genes. By releasing strong, unrelenting growth-
stimulating signals into a cell, oncogenes can drive cell growth 
ceaselessly." (1994) The key to normal, healthy cell growth is 
moderation, a balance between growth-promoting proto-oncogenes and the 
genes that regulate cell growth. 
The genes that regulate cell growth are known as anti-oncogenes, or 
more commonly, tumor suppressor genes. Like all genes, since there are 
two chromosomes, there are two copies of each tumor suppressor cell. 
So, even if a tumor suppressor gene is knocked out by mutation, the other 
14 
• can serve the function and suppress carcinogenesis. It is only when the 
second copy is knocked out that carcinogenesis arises. This theory is 
known as Knudson's hypothesis, or the atwo-hit" theory. (Knudson, 1971) 
Fortunately, the chances of this happening are very small. In fact, the 
chance of losing one copy of a tumor suppressor gene is approximately 1 in 
1 million; the chance of losing both copies is 1 in 1 billion per cell 
generation. (Weinberg, 1994) There are not as many known tumor 
suppressor genes as proto-oncogenes. Three tumor suppressor genes will 
be covered in detail in this paper. The first is the p53 tumor suppressor 
gene on 17p, the second is the BACA 1 tumor suppressor gene on 17q, and 
• the third is the BRCA2 gene on 13q. Other tumor suppressor genes that 
will be mentioned only briefly are those found on 3p, 7q, and 13q. 
• 
The ·two-hit" theory is sometimes compromised. For example, one 
allele of the BRCA-1 gene is lost to a high degree in some families. This 
makes the odds of developing breast cancer substantially greater in these 
individuals. For this reason, BACA 1 is sometimes referred to as a 
·familial" breast cancer gene. As mentioned earlier, proto-oncogenes and 
tumor suppressor genes both play a part in tumorigenesis. Robert 
Weinberg has a great analogy for this concept, "So, a tumor can arise by a 
stuck accelerator (an activated oncogene) or a faulty brake (inactivated 
15 
• growth-suppressing gene). (1994) Tumors that arise from both are 
especially dangerous. 
p53 
The most common tumor suppressor gene mutation associated with 
human tumor formation is p53. (Hollstein et al., 1991; Trudel et al., 1992; 
Weinberg, 1994) Indeed, p53 mutations are found in DNA samples from 
more than half of all human tumors. In fact, mutations in the p53 tumor 
suppressor gene are the most common changes found in breast cancer. The 
• incidence of mutations in this gene are 15-50%, depending on the stage of 
the tumor and the method of detection. (Bartek et al., 1990; Davidoff et 
al., 1991; Osborne et al., 1991) On average, p53 is mutated in 
approximately 30% of sporadic breast cancers. (Prosser et al., 1991) p53 
is located on the short arm of chromosome 17. (Fig. 11) 
• 
How do p53 mutations lead to tumorigenesis? Basically, since it is 
a tumor suppressor gene, when it is mutated, it loses its function and 
tumors are free to grow. However, the total mechanism is somewhat more 
complicated. The passage of cells through the cell cycle depends on the 
activity of enzymes know as cyclin-dependent kinases, or Cdks. (Marx, 
16 
• 1993) The enzyme known as Cdk2 pushes cells out of the first phase of 
the cell cycle into the DNA synthesizing phase. The p53 gene encodes tor a 
protein that induces the gene that produces a 21 kilodalton protein known 
• 
• 
as either Cip1 (Harper and Elledge, 1993), Waf1 (EI-Diery et al., 1993), or 
sdi1 (Smith et al.). The Cip1, or Cdk-interacting protein, is a good 
inhibitor of Cdk2. In other words, it acts as a brake for cellular division 
by inhibiting the enzyme that pushes cells into the replication phase. 
When a mutation arises in the p53 gene, the protein the gene codes for 
does not work properly, and it is unable to inhibit the enzyme Cdk2. As a 
result, growth is uncontrolled . (Fig. 12) 
Other research shows alternative or additional tumor suppressing 
mechanisms of p53. There are several publications documenting the 
ability of p53 to actually suppress the promotor sequences of certain 
oncogenes by interacting with them. (Ginsberg et al., 1991; Santhanam et 
al. , 1991; Kley et al., 1992; Mack et al., 1993) Promoter sequences are 
sections of DNA that lie before and outside a gene. They help DNA 
replication get started by providing a ·docking site" for the replication 
machinery of a cell, DNA _polymerase. Other researchers believe p53 acts 
to induce apoptosis, or programmed cell death, on tumor cells that have 
avoided destruction with the help of oncogenes. (Hermeking and Eick, 
17 
• 1994) In any case, the normal p53 gene acts as a tumor suppressor. When 
it is mutated, it loses its function, leading to tumorigenesis. 
As mentioned earlier, the majority of cancers are sporadic. That is , 
most cases of cancer develop within the cells on their own, and are not 
inherited. Loss of the p53 gene is sporadic. It is not linked to familial 
breast cancer cases. The Handbook of Gene Level Diagnostics in Clinical 
Practice explains after thorough testing of familial breast cancer DNA, 
"No structural abnormalities in the p53 genes were noted, discounting the 
possibility that structural abnormalities of the p53 gene contribute to the 
heritabie predisposition for the development of breast cancers." (Kovach, 
• 1991) More specifically, "The incidence of p53 germline mutations as a 
cause of familial (Borrensen et al., 1992; Warren et al., 1992; and Prosser 
et al. , 1991 ), early onset {Sidransky et al., 1992), or bilateral breast 
cancer (Lidereau et al., 1992) is low, less than or equal to 1%." (Elledge et 
• 
al., 1993) 
Even though p53 mutations are not found in familial breast cancer, 
the fact that p53 mutations occur so often in sporadic breast cancer make 
them extremely dangerous and life-threatening. The high rate of incidence 
of this mutation is not the only factor that makes it dangerous. Patients 




prognosis . (Elledge et al., 1993) This is due to the fact that tumors 
resulting from p53 inactivation are very resistant to treatment. (Lowe et 
al., 1994) Besides being difficult to treat, once p53-induced tumors are 
taken out or remedied, tumors often come back. •43% of women with a 
p53 altered tumor had a recurrence by 5 years, while only 21 % of women 
without an alteration had a recurrence: (Elledge et al., 1993) To 
reiterate, p53 mutations are so life-threatening because they occur often 
in tumors, p53-induced tumors are very resistant to treatment, and the 
chance of recurrence in women with p53-altered breast tumors is twice 
as common as women with tumors that did not contain a p53 mutation . 
BRCA1 
While the majority of breast cancer cases are sporadic, or occur 
naturally, an estimated 10% are suspected to be familial, or inherited. 
(Lalle et al., 1994) The tumor suppressor gene p53 appears to play no part 
in the development of familial or early-onset breast cancer. However, the 
tumor suppressor gene known as BRCA 1 _has a major role in breast cancer 
occurring in a familial or early-onset context, and a very minor role in 
sporadic cases. (Hall et al., 1990; Futreal et al., 1994) The BRCA1 gene is 
19 
• also connected to ovarian cancer in families with a history of breast cancer. (Narod et al., 1991) In other words, the BACA 1 gene confers 
susceptibility to breast and ovarian cancer, but is more closely linked to 
breast cancer. The BACA 1 gene lies on the long arm of chromosome 17, 
around 17q11-21. (Figs. 13 & 14) The connection of familial breast cancer 
has been documented by Lindblom et al., • ... tumors from breast cancer 
families with early onset lost heterozygosity on 17q more than any other 
tumors." (1993) It is estimated that BACA 1 is responsible for breast 
cancer in one-half of the families with multiple cases of breast cancer, 
and almost all of the families with both breast and ovarian cancer in their 
• histories. (Easton et al., 1992) BACA 1 · is estimated to be responsible for 
5% of all breast cancers , but 25% of early-onset cases occurring in women 
less than 30 years of age. (Claus et al., 1991) 
• 
The role of the BACA 1 tumor suppressor gene appears to be very 
similar to that of the p53 tumor suppressor gene. It is most likely BACA 1 
encodes a protein that is a negative regulator of cell growth. (Miki et al. , 
1994) Mutations in the BACA 1 gene knock out the functionality of the 
protein. In fact, Miki et al. have shown that three of the five mutations 
they found in familial breast tumors were mutations that caused 
production of the protein to cease, thus ruining the efficacy of the protein . 
20 
• Their work also supported the idea that the protein acts as a negative 
regulator of cell growth, ·The nature of the three mutations observe9 in 
the BACA-1 coding sequence is consistent with production of either 
dominant-negative proteins or non-functional proteins: ( 1994) A dominant-
negative protein is one that interferes with the job normal proteins do, 
and destroy tumor-suppressing capabilities in another way. The BACA 1 
tumor suppressor gene obeys Knudson's hypothesis, or the "two-hit" 
theory. In familial breast and ovarian cases, one of the tumor suppressor 
alleles is lost at birth, meaning two good copies are not received from the 
parents. This is why it is referred to as familial breast cancer. With one 
• copy gone, it is sufficiently easier to develop cancer because i1 is much 
easier to lose one allele from mutation than two. (Smith et al., 1993; 
Kelsell et al., 1993) 
• 
Statistical evidence taken from families with a history of early-
onset breast and ovarian cancer support the hypothesis that the BACA 1 
gene region is responsible. Tumors studied from affected BACA 1 carriers 
show loss of heterozygosity that invariably involves loss of the normal 
BACA 1 allele. (Smith et al., 1992) In one study, 50% of breast carcinomas 
and 57% of ovarian carcinomas showed loss of heterozygosity in the 
BACA 1 region, meaning loss of one BACA 1 allele. (Futreal et al., 1994) 
21 
• These levels are consistent with numerous other studies . An inherited mutation leading to loss of the BRCA 1 tumor suppr~ssor 
gene is very dangerous. Fortunately, the familial, early-onset breast 
cancer disease is not completely penetrant. Penetrance is the measure of 
how many people with a gene develop the characteristic carrie.d by the 
gene. In the case of BRCA 1, penetrance is a measure of how many carriers 
of a mutated BRCA 1 gene develop breast cancer. There is a chance that 
the good copy of the gene that remains in the cells will never be taken out 
by single mutations. As Hall et al. point out, " ... the disease is not 
completely penetrant among susceptible persons, with expression 
• depending on gender, age, and non-genetic risk factors.• (1990) First, it 
appears that only women carriers of the mutated BRCA 1 gene have 
increased risk. While men do in fact get breast cancer (but much more 
rarely}, BRCA1 does not appear to play a role in its development. However, 
men with the mutated BRCA 1 gene are at an increased risk of prostate 
cancer, about 3.5 times greater probability than non-carriers. (Ford et al., 
1994) Furthermore, both women and men carriers are about four times as 
likely to develop cancer of the colon than non-carriers. (Ford et al., 1994) 
(Fig. 15) 
While not completely penetrant, loss of the BRCA 1 gene is still very 
• 22 
• dangerous, especially to older women. (Figs. 16 & 17) The probability that 
a female carrier of BRCA 1 will be diagnosed with breast cance_r is 
approximately 73% by age 50 and 87% by age 70. (Easton et al., 1992) 
Goldgar et al. suggest the probability is 40% by age 50 and 90% by age 70. 
(1994) Hall et al. estimate the probability of developing breast cancer in 
women that carry the defective gene is 37% by age 40, 66% by age 55, and 
82% over the lifetime. (1990) The probability for non-carriers is 0.4% by 
age 40, 2.8% by age 55, and 8.1 % over the lifetime. These statistics alone 
are threatening, but BRCA 1 also confers an increased probability to 
develop ovarian cancer, approximately 29% by age 50 and 44% by age 70. 
• (Ford et al., 1994) An inherited BRCA1 mutation is severe, as a carrier 
has a lifetime risk of either breast or ovarian cancer of close to 100%. 
(Ford et al., 1994) This statistic alone demands more attention be spent 
to this life-threatening disease. 
• 
What explains the variable penetrance of the BRCA 1 susceptibility? 
It .is largely unknown. It is believed that mutations in BRCA 1 only cause 
susceptibility to breast or ovarian cancer in certain stages of breast and 
ovary development. (Futreal et al., 1994) As mentioned earlier, the 
penetrance is dependent on gender, age, and non-genetic risk factors. The 





risk factor that determines penetrance is age of first pregnancy. The 
younger a woman is when she is pregnant for the first time, the lower her 
risk for developing breast cancer. Women whose first pregnancy occurs 
after 29 years of age are twice as likely to develop breast cancer as those 
women who are first pregnant before the age of 20. (Goldgar, 1994) Also, 
late age at menopause and obesity confer an increased risk of breast 
cancer development. (Goldgar et al., 1994) 
Recently, it has been proposed in the literature that there are two 
different susceptibility alleles for the BACA 1 gene. One confers a high 
susceptibility to breast cancer and a low susceptibility to ovarian cancer, 
and the other does just the opposite . If present, BRCA1-alpha- confers a 
breast cancer risk of 91 % by age 70 and an ovarian cancer risk of 32% by 
age 70, while BACA-beta confers a 70% breast cancer risk by age 70 and 
an ovarian cancer risk of 84%. (Ford et al., 1994) Together, they confer 
the 87% breast cancer risk and 44% ovarian cancer risk noted above. The 
two-subgroup hypothesis better explains the observed patterns of breast 
and ovarian cancer risk. 
BRCA2 
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• An even more recent development has been the proposal of another BACA tumor suppressor gene. While BACA 1 is most closely associated 
with families that have both breast and ovarian cancer in their history, 
BACA2 is responsible for most cases of male breast cancer. (Ponder, 
1994) The two are similar in the fact that they are each responsible for 
one-third of the early-onset, familial breast cancer cases. (Ponder, 1994) 
Together, they are responsible for two-thirds of all early-onset cases, 
and slightly over 5% of all breast cancer cases. (Futreal et al. , 1994) 
BACA2 does not appear to be involved with increased susceptibility to 
ovarian carcinoma. (Futreal et al., 1994) The gene has been localized to 
• chromosome 13q12-13. (Futreal et al. 1994) 
• 
Others 
Several other chromosomal abnormalities have been associated with 
breast cancer development. For example, it has been suggested that there 
are two tumor suppressor genes on the short arm of chromosome 3, at 13-
14 and 24-26. (Chen et al., 1994) This study found loss of heterozygosity 
in the first region in 41 % of the· cases and loss of heterozygosity in the 
second region in 45% of the cases. It was also discovered that most of the 
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• losses were a result of actual physical deletion of those segments of the chromosome. 
The retinoblastoma (Rb) gene is also a tumor suppressor gene. It is 
a 200 kb gene that encodes a 11 O kilodalton protein which acts as a 
mediator of the cell cycle. (Croghan, 1993) The Rb gene is thought to 
achieve growth-suppressive activity by binding to a transcription factor 
and inhibiting copying of the DNA. (Trudel et al., 1992) Possibly for this 
reason, tumors linked to loss of the Rb gene are quite serious, as there is 
a positive correlation between Rb and large tumor size. (Spandidos et al., 
1992) The gene is located at 13q14, very near the location of the newly 
• proposed BRCA2 gene at 13q12-13. It is possible that some of the loss of 
heterozygosity attributed to the retinoblastoma gene over the past 
several years was due to the then unknown BRCA2 gene. Or, it is possible 
that the reverse is the case. Either way, more research is necessary in 
this area to determine responsibility and possible interaction between the 
two tumor suppressor genes. 
• 
There also appears to be a tumor suppressor gene on chromosome 
7q31. (Bieche et al., 1992) Loss of heterozygosity in the region of 7q31 
was detected in 41 % of breast tumor DNA. (Bieche et al., 1992) Since this 
is sufficiently higher than the 0-10% loss at other random regions of the 
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• DNA (Mackay et al., 1988; Bieche et al., 1990), it is a significant finding. 
• 
• 
Patients with a mutation in the 7q31 region had a significantly higher risk 
of relapse compared to patients without a 7q31 mutation (55% and 21%, 
respectively). They also had a much greater mortality rate (41 % vs. 15%). 
In addition, patients with the mutation had a shorter metastasis-free and 
overall survival than those without the mutation. (Bieche et al., 1992) 
The correlation between loss of the 7q31 gene and shorter metastasis-
free survival leads some to believe that the gene not only serves as a 
tumor suppressor gene, but as a metastasis suppressor gene as well. 
(Bieche et al., 1992) 
Myths 
It is impossible in today's world to make it through one week, maybe 
even one day, without hearing something about breast cancer. Reports in 
the press and conversations with other people barrage us with the latest 
info on what causes breast cancer. As a result, there are many myths. 
However, not all of the talk is erroneous; there are some environmental 
factors that contribute to breast cancer development. Let us start with 
the myths . First, research conclusively shows that diet does not cause 
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• breast cancer. In one study, two very large experimental groups of women 
were assembled, about 800 in each. One group consisted of women _ with 
confirmed cases of breast cancer. The other group consisted of women 
who were determined to be free of cancer. The diet of the two groups, 
both in the past and present, was monitored. The investigators found no 
connection between the amount of total protein, total fat, saturated fat, 
unsaturated fat, or total carbohydrates and increased risk of breast 
cancer. (Katsouyanni et al., 1994) In short, diet was not related to the 
development of breast cancer. 
The second myth that must be dispelled is the risk from surgical 
• implants for breast augmentation. Breast implants do not cause breast 
cancer. One study emphasized the fact that in the seven-year period from 
1973-1979, there were 34,000 women who had their implants for at least 
ten years. In the seven year period from 1980-1986, there were 343,000 
women who had their implants for at least ten years. So, in other words, 
approximately ten times more women had possessed their implants for a 
minimum of ten years in the second time period than the first. 
Regardless, the total number of breast cancer cases per 100,000 women 
were identical for the two time periods. (Engel, 1992) In other words, 
even though there were ten times as many women with implants, there 
• 28 
• was no increase in breast cancer overall. It may be argued that, in fact, 
there was an increase due to implants, but it was obscured by a decr~ase 
somewhere else. This is unlikely and even if it was likely, it would not 
alter the findings to any noticeable degree. Even if the data were 
• 
• 
interpreted for a worse-case scenario, it would only amount to an 
additional 2.8 breast cancer cases nationwide each year. (Engel, 1992) 
This figure is hardly significant. Engel sums it up quite well, ·with an 
allowance of a 10-year latency period, the data did not reveal an effect on 
breast sarcoma incidence from the increased frequency of breast 
implantation procedures." (1992) 
One myth that has some degree of truth concerns the · intake of 
alcohol on breast cancer development. In one study, people who drank 
more than three drinks per day were 3 times more likely to develop breast 
cancer, while those who drank more than four drinks were almost four 
times as likely. (Katsouyanni et al., 1994) More moderate drinkers did not 
have an elevated risk. Also, the amount of consumption had less to do 
with cancer development than the frequency of drinking. In any case, high 
levels of alcohol consumption are associated with higher breast cancer 
risk while diet and breast implants are not. 
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• Experimental-
The presence of oncogenes and the loss of tumor suppressor genes in 
the tumor tissue of women who had undergone prophylactic mastectomy 
sugary at the Mayo Clinic was studied. Since many prophylactic 
mastectomies have been performed at the Mayo Clinic, there is an 
extremely large amount of material from many patients on which the 
study was based. My role in the study consisted of examining the normal 
and tumor breast tissue of sixteen women who had prophylactic 
mastectomies at the Mayo Clinic for loss of the tumor suppressor genes 
• p53 and BACA 1. 
• 
Methods-
For each patient, two paraffin blocks containing tissue samples 
were obtained from tissue registry. One block contained tissue from the 
cancerous breast and one block contained tissue from the non-cancerous 
breast. 4 um sections were cut from the blocks using a Leica-Jung 
RM2025 microtome. Sections were mounted on five acetate microscope 
slides and six sterile glass microscope slides. The first and last sections 
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• were each mounted on glass and placed in a 62oC drying oven to melt the 
paraffin and make the sections adhere to the slides. The slides were Jhen 
stained with hematoxylin and eosin to be used by the pathologist to insure 
cancerous tissue was present. (Fig. 18) These areas were marked . By 
examining the first and last sections taken from the paraffin block, the 
pathologist confirmed that we were using tissue of the appropriate type 
in each trial. 
• 
• 
The acetate sheets were used for cancerous and non-cancerous DNA 
acquisition. First, the slides were placed in Histo-Clear for ten minutes. 
The areas the pathologist had indicated on the glass slides as being 
cancerous and non-cancerous tissue were excised out of the acetate slides 
using a sterile scalpel. The pieces of tissue-coated acetate were placed 
in 1.5 ml screw-top Sarstedt ubes that had been sterilized in a Fisher UV 
Crosslinker for 1 O minutes. The DNA was digested off the slides by 
placing 2 ul of Protease K (20 mg/ml) and 100 ul of DNA Paraffin 
Extraction Buffer (100 mM Tris HCI, 2 mM EDTA, pH 8) in each tube. They 
were then incubated in a 370c shaker overnight. After the DNA was 
completely dissolved, the tubes were boiled for ten minutes to destroy the 
activity of the Protease K. 
Polymerase Chain Reaction (PCR) was then used to amplify the DNA 
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• of each sample. The reaction mixture contained six main substances . First, 2.0 ul of patient DNA was used as the template in the amplificaJion. 
Second, 3.0 ul of PCR buffer (containing 200 uM of each deoxynucleotide 
except cytosine, Mg2+, and Tris buffer), was added to maintain the 
reaction and provide the materials for replication. Third, 0.1 ul of 
forward primer and 0.1 ul of reverse primer were used. Primers anneal to 
specific sites on a DNA strand and provide a spot to begin DNA replication. 
(Fig. 19) Where a primer anneals depends on its base sequence. So by 
choosing the base sequence of a polymer, the area amplified can be 
controlled. In this manner, one can amplify only the part of the genome 
• that contains the gene to be studied. So, to study the loss of p53 and 
BRCA1, primers (we·senba.ch) flanking the areas where these genes are 
found were used. The primers used for the gene p53 were D17S786 and 
D17S807, which cover areas on chromosome 17p. The primers used for the 
BRCA1 gene were D17S796 and D17S250, which cover areas on 
chromosome 17q. Fourth, 0.1 ul of Taq DNA polymerase, the enzyme that 
polymerizes, or connects, the deoxynucleotides in the correct sequence to 
• 
match the template DNA, was added. Fifth, 0.1 ul of cytosine 
radioactively labeled with 32P (produces beta particles) was added for 
imaging purposes. Sixth, the remainder of the reaction mixture consisted 
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• of water, to bring the total volume up to 15 ul (9.7 ul of water). In two cases, 4.0 ul of template DNA was needed for good results, so the water 
was adjusted to 8.7 ul. 
The reaction mixtures were then placed in 0.5 ml Thin-Walled 
GeneAmp Reaction Tubes by Perkin-Elmer. These tubes were then placed 
in an Ericomp Thermal Cycler. The reaction was run at 95oC for 1 minute, 
55oC for 2 minutes, then 72oC for 1 minute. This cycle was completed 35 
times. Then, the tubes were incubated at 72oC for 10 minutes, and then 
maintained at room temperature. The purpose of the 95oC step was to 
denature the DNA, or separate the two coiled strands of polymerized 
• deoxynucleotides. The 550c step anneals the primers to the · separated 
strands of DNA. The purpose of the 72oC step is to elongate the newly· 
forming strands of DNA. (Fig. 20) 72oC is an optimal temperature for Taq 
polymerase to function, hence, keeping the reaction at this temperature 
synthesizes the DNA the fastest. The cycle is then repeated, only this 
time, there are four strands of DNA after the denaturing step. Therefore, 
primers attach to four strands and four new strands are started during the 
elongation phase. This is repeated again and again, for a total of 35 
times, each time the number of strands growing geometrically (2, 4, 8, 16, 
32, 64, 128, 256, ... ) The final 72 degree step allows time for all the new 
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• strands to continue synthesizing to the end of the strand. After 35 cycles of PCR, there are 1225 strands of DNA. (Fig. 21) This is the central tenet 
of Polymerase Chain Reaction, it is a chain reaction. For this reason, it 
takes little time to greatly amplify the amount of DNA. As a result, many 
scientific trials can be conducted off a very small amount of tissue. T h e 
success of PCR is very well documented. However, the success of PCR on 
DNA from paraffin-embedded tissue is not as high as DNA from fresh 
blood, but it still is adequate and attainable. (Wright and Manos, 1990; 
Bowcock et al. , 1993; Chamberlain et al., 1993) 
To analyze the DNA, polyacrylamide gel electrophoresis (PAGE) was 
• completed. PAGE is a technique used to separate linear polymers on the 
basis of their size. Polyacrylamide, when it is mixed with ammonium 
persulfate and TEMED, forms a mesh gel. An electric field is then applied 
to the gel via electrodes in a buffer solution. Since DNA is negatively 
charged, it will migrate from the negative to the positive electrode , as 
opposite charges attract. Smaller fragments move more quickly through 
the gel than larger fragments, as the larger fragments have more 
difficulty fitting through the spaces in the mesh gel. This allows one to 
separate the fragments according to molecular weight. 
The gel was made by pouring a mix of 6% polyacrylamide (19:1 
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• acrylamide : bisacrylamide), 7% urea, 1 % ammonium persulfate {APS - 550 
ul of 10%), and 0.5 X TBE buffer between two glass plates. This buffer 
was made with 0.045 M Tris-Borate (54 g Tris base, 27 .5 g boric acid) and 
0.001 M EDTA (pH 8.0). After the gel had set, it was loaded with the DNA 
samples. Before they were loaded, a loading buffer was added (98% 
deionized formamide, 10 mM EDTA, 0.025% xylene cyanol FF, and 0.025 
bromophenol blue). The loading buffer had three purposes. First, it 
increased the density of each sample, making it easier to load the sample 
into the wells in the gel. Second, it added color, simplifying the loading 
process. Third, the buffer contains dyes that migrate at predictable rates 
• through a gel placed in an electric field. Therefore, it was possible to 
estimate the location of the DNA fragments by judging where the dyes 
were in the gel. 
• 
There are primarily two dyes in the loading buffer, a teal green and a 
deep blue. The molecules that make up each dye have a certain molecular 
weight. Each molecular weight can be translated into an approximate 
base-pair range. The teal green dye runs with about 120 base-pair 
fragments, while the deep blue runs with 150-155 base-pair fragments. 
Since the primers amplify alleles of 114-170 base-pairs, the green dye 





Scientific FB-Seq-3545 Sequencing System connected to a power supply 
set at 3000 V, 75.0 W, and 200.0 mA. Next, the gels were disconnected 
and transferred to paper and dried on gel dryers for approximately 1.5 
hours. Once the gels were dry, they were placed in autoradiography 
intensifying film cassettes with a single piece of Kodak X-OMAT AR 
Imaging Film (35 X 43 cm). The film was exposed overnight at room 
temperature. If the radioactive signal was very weak, the film was 
exposed overnight at -75oC. After being exposed, the film was developed 
using a Kodak X-OMAT developer. All film work was completed in a 
darkroom. 
As explained earlier, the primers used in the PCR were designed to 
anneal to the areas of the chromosome where the tumor suppressor genes 
p53 and BRCA 1 are found. So, the radioactively-labeled fragments on the 
gel contained the section of DNA containing the p53 or BRCA 1 genes. Loss 
of heterozygosity was used to determine absence of these two genes. Only 
heterozygous individuals, or those with two slightly different alleles for 
each gene, could be used for this method. A heterozygotic sample will 
show two bands of DNA on the film, as different alleles of the same gene 
have slightly different lengths. By comparing a set of normal 
heterozygous alleles from non-cancerous breast tissue to the alleles 
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• obtained from cancerous breast tissue, it is possible to determine loss of heterozygosity in the cancerous tissue. Loss of heterozygosity is 
apparent when, for example, the top alleles are of near identical intensity 
in the normal and tumor tissue, while the bottom allele of the tumor 
tissue is much lighter, or less intense, than the normal tissue. (Fig. 22) 
When a allele is lighter, it has less radioactive label, and hence less DNA. 
Since the PCR conditions were the same for both types of tissue, there 
should be the same amount of DNA. Less DNA suggests loss of the allele in 
the tumor tissue for some reason. When the loss of DNA is in the p53 or 
BACA 1 regions, a loss of that tumor suppressor gene is indicated. 
• Therefore, in effect, we were looking for lighter tumor suppressor gene 
bands in the cancerous tissue than in the non-cancerous tissue. If the 
tumor suppressor genes were lost in the cancerous tissue when they were 
not in the non-cancerous tissue, there is a good possibility they were 
responsible for, or associated with, the development of the cancer. 
• 
Results-
The primers D17S796 and D17S786 were used to detect loss of 
heterozygosity of p53. (Fig. 23) In the region amplified by the primer 
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• D17S796, loss of heterozygosity was detected in patients 1 and 11. 
Patients 7 and 8 were heterozygous with no loss. Loss could not be 
determined in patients 6, 12, and 15 because of homozygosity in the 
region. Loss could not accurately be determined in patients 2, 3, 4, 5, 9, 
1 O, 13, 14, and 16. In the region amplified by the primer D17S786, loss of 
heterozygosity was detected in patients 1, 2, 6, 9, 11, and 15. Patient 7 
was once again heterozygous with no loss. Loss of heterozygosity could 
not be determined in patients 3, 5, 12, and 14 because of homozygosity. 
Loss could not be ascertained on patients 4, 8, 10, 13, and 16. 
To detect loss of heterozygosity in the region containing BACA 1, the 
• primers D17S250 and D17S807 were implemented. (Fig. 23) Patients 1 
and 9 showed loss of heterozygosity in the region flanked by primer 
D17S250. No loss was detected in patients 5, 14, and 15. Patients 2, 4, 6, 
7, 11, and 12 were homozygous. Loss could not be determined in patients 
3, 8, 10, 13 and 16. The region amplified by the primer D17S807 showed 
loss of heterozygosity in patients 1, 4, 6, 8, 9, and 12. Patients 2, 7, 14, 
and 15 showed no loss in the region. Loss of heterozygosity could not be 
determined in patients 3, 5, 11, and 16 due to homozygosity. Patients 10 
and 13 could not be determined. (Fig. 24) 
Excluding indeterminate trials, the region amplified by D17S796 
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• showed loss of heterozygosity in 28.6% of patients, no loss in 28.6% of 
patients, and 42.9% of the patients homozygous. In the region ampl_ified 
by D17S786, 54.5% of the patients showed loss of heterozygosity, 36.4% 
showed no loss, and 9.1 % were homozygous. Considering both primers, the 
short arm of chromosome 17, where p53 is located, showed loss of 
heterozygosity in 44.4% of patients, no loss in 33.3% of patients, and 
22.2% of the patients homozygous. 
Also ignoring indeterminate trials, the region flanked by D17S250 
showed loss of heterozygosity in 18.2% of patients, no loss in 27 .3% of 
patients, and 54.5% of the patients homozygous. The region amplified by 
• D17S807 showed 42.9% of the patients had lost one of the heterozygotic 
alleles, 28.6% had no loss, and 28.6% were homozygous. When both. 
primers are cons·dered, the long arm of chromosome 17, containing 
BACA 1, showed loss of heterozygosity in 32% of patients, no loss in 28%, 
and 40% of the patients were homozygous and could not be detected. 
• 
In patients purely heterozygous in the region of interest, 50% 
showed loss in the region amplified by D17S796. The region amplified by 
D17S786 showed loss in 60% of heterozygous patients. In the region 
amplified by D17S250, 40% of the heterozygous individuals showed loss, 
while 60% of the heterozygous patients showed loss in the D 17S807 
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• region. 
In summary, the region on 17p containing p53 showed loss in 5'? .1 % 
of heterozygous patients. The BACA 1-containing region on 17q showed 
loss in 53.3% of heterozygous patients. (Fig. 25) 
Discussion-
It was very unfortunate that the results of some of the trials were 
indeterminate. Even after many repetitions with different reaction 
concentrations, some trials remained inconclusive. In the same fashion, 
• . the fact that some patients were homozygous in the amplified regions 
• 
created problems, since homozygous individuals cannot be analyzed by 
PAGE. Because this possibility was known before the experiment was 
begun, primers with high HET scores were used. The HET score expresses 
the probability of heterozygosity of the general population in the 
amplified region. The value is expressed as a decimal between O and 1. 
The decimal can be converted into a percentage. For example , primer 
017S796 has a published HET score of 0.824. (Weisenbach) This indicates 
that a given sample will be heterozygous in the amplified region 82.4% of 
the time. In other words, 82.4% of the population is estimated 
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• heterozygous in the region. This is a good HET score; primers with HET 
scores lower than 0.65 would not be very useful for this study. Even 
though the HET scores were pretty high (0.773-0.862), some patients were 
still homozygous and unreadable in terms of loss of heterozygosity. 
When indeterminate and homozygous trials were discarded, the 
observed loss of heterozygosity of the region containing p53 was very 
close to the expected loss. As mentioned earlier, p53 is mutated in 50% 
of all cancers. (Weinberg, 1994) More specifically, it is mutated in 15% of 
in situ cases and around 50% of serious cases. (Bartek et al., 1990; 
Davidoff et al., 1991 ; Osborne et al., 1991) The observed value of 57% in 
• our study matches this very closely. As mentioned earlier, thete were a 
number of indeterminate trials, 14 of 32 to be exact. If the indeterminate 
trials were more conclusive, we might see an even closer match. The 
observed HET scores of the p53-containing fragments were extremely 
close to the HET scores suggested by the manufacturer. The average 
observed HET score was 0.777 compared to the average reported value of 
0.793. So, additional trials to lower the number of homozygous trials 
would be unprofitable unless a different primer was used. Even so, the 
number of readable trials would not increase noticeably, and other 
complications may develop . 
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• The results of the BACA 1 trials do not appear as accurate as those of the p53 trials. The region containing BACA 1 was mutated in 53% of_ the 
heterozygous individuals. This is sufficiently higher than the reports 
estimating that BACA 1 is mutated in 5-10% of all breast cancer cases. 
This discrepancy can be explained by four main theories. First, 7 of 32 
trial were indeterminate. It is possible that all of these trials show no 
loss of heterozygosity; this would bring down its percentage. On the other 
hand, it is also possible that all indeterminate cases would show no loss. 
Both of these situations are unlikely; it is most likely that some trials 
show loss and others show no loss However, either one may · have a 
• greater chance to have complications that prevent accurate determination. 
• 
This is impossible to accurately determine in my study, so we must be 
satisfied with the possibility that some error may have arisen from 
indeterminate trials. 
Second, the number of homozygotic individuals was much higher than 
expected. Using the manufacturers' reports, we calculated a HET score of 
0.839 for the two primers combined , after the indeterminate trials were 
discarded. However, the observed HET score for the two primers used for 
BACA 1 amplification was 0.60. Indeed, we observed 6 more homozygous 
individuals than was expected. If we had observed more heterozygous 
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• individuals, we may have detected more individuals with no loss , and achieved more expected results. 
Third, because loss of heterozygosity was examined in this study, it 
is possible that we inadvertently determined more trials showing loss 
when they were, in fact, not showing loss. This situation is always 
possible when dealing with results such as the intensity of bands on 
autoradiography film . The distinction between loss and no loss is very 
minute and errors are possible. The fact that we looked for loss of 
heterozygosi~y may hav€ causod us to "lean" to loss when the call was 
close. Use o1 intensity-detecting computer software such as IMAGE may 
• aid in more effectively judging loss of heterozygosity in further trials. 
• 
However, the fac t at p53 showed no major discrepancies suggests that 
the determination of loss of heterozygosity was quite accurate. If 
inadvertent favoritism was present in determination of the BACA 1 
results, it should havo been noticeable in the p53 results . It was not. 
Therefore , it is likely the loss of heterozygosity results are accurate in 
both the p53 and BACA 1 trials. 
Fourth , the discrepancy may have been caused by the characteristics 
of the group studied. It was mentioned earlier that 50% of early-onset, 
familial cases of breast cancer showed a BACA 1 mutation. (Futreal et al. , 
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• 1994) Since women with early-onset, familial breast cancer are the most likely to have prophylactic mastectomies, it is more likely that tt:iese 
women carry the BACA 1 mutation. Indeed, we observed BACA 1 mutations 
in 53% of the women in our study, which very closely matches the report 
suggesting 50% of early-onset, familial cases have a BACA 1 mutation. 
This suggests that the loss of BACA 1 results are accurate. 
Conclusions-
It has been shown that 57% of women had lost the p53 tumor 
• suppressor gene in the cancerous breast tissue removed during normal and 
prophylactic mastectomy surgeries. Furthermore, 53% of these women 
had lost the BACA 1 tumor suppressor gene in the same cancerous tissue. 
These results closely correlate with literature suggesting p53 is 
commonly mutated in cancers, especially those of serious grade in the 
breast. The results also agree with reports suggesting BACA 1 is 
commonly mutated in familial , early-onset breast cancer cases. 
• 
All of the following risk factors: serious tumor grade, early age of 
diagnosis, and history of cancer, especially of the breast, make patients 
good candidates for prophylactic mastectomy surgery. These same risk 
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• factors are characteristics of genetic susceptibility to breast cancer. It 
is known that genetic susceptibility increases the risk of cancer 
recurrence. However, until this study, there has been no concrete evidence 
of a connection between perceived high risk of recurrence, and therefore 
prophylactic mastectomy surgery, and actual genetic proof of 
susceptibility. In other words, it has never been determined that the 
women who were having prophylactic mastectomies had genetic material 
that made them get cancer. This study has shown that women who have 
had prophylactic mastectomy surgery have greater genetic susceptibility 
to breast cancer development than other women . 
• 
• 
More importantly, this study has shown that prophylactic 
mastectomy surgery is a viable and worthwhile treatment to prevent 
breast cancer recurrence. It is hoped that this information will increase 
the knowledge of breast cancer. For the same reason, this paper has 
attempted to explain what cancer is while describing how the genetics of 
a person cause or contribute to its development. Most of all, it is hoped 
that this paper will emphasize the severity of this disease in the United 





Table 1. Magnitude of the Breast Cancei;,?roblem• 
Year and 
percentage Incidence Mortality 
change Cases Deaths rate rate 
1970 69,000 30,000 79.9 26.6 
1980 109,000 36,000 85 .2 26.4 
1990 150,000 44,000 102.0 27.3 
Percentage change 117.4 46.7 27:J', 2.6 
• Rates are age adjusted to the I 970 population. Data from Mil~er A, Ries LAG, 
Hankey BF, Kosary CL, Harris A, Devesa 55, Edwards BK, edito . SEER Cancer 
Statistics Review: 1973-1990. Bethesda, MD: National Cane Institute, 1993. 
NIH Publication No. 93-2789; and American Cancer Society. Cancer facts and 
figures-I 994 . American Cancer Society, Inc., 1994. Publication No. 5008. 94. 
Sondik et al., 1994 • 
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Table 2. Breast Cancer Incidence and.Mortality Rates per 
100,000 Women for Black and White Women, 1989 
Incidence (age) Mortality (age) 
All All 
Race <50 50+ ages <50 50+ ages 
Whites 32.2 346.2 109.1 5.9 93.9 27.5 
Blacks 30.9 263 .5 87.8 9.2 96.0 30.4 
All races 31.6 333.4 105.5 6.2 93.1 27.5 
Oat.i from Miller BA, Ries LAG, Hankey BF, Kosary CL, Harris A, Oevesa 55, 
Edwards BK, editors. SEER C.mcer Statistics Review: 1973-1990. Bethesda, 
MO: National Cancer Institute. 1993. NIH Publication No. 93-2789. 
Sondik et al., 1994. 
Table 3. Percentage Change in Breast Cancer Incidence 
and Mortality Rates for Black and White Women, 
1973-1989 
Incidence (age) Mortality (age) 
·' All All 
Race <50 50+ ages <50 50+ ages 
Whites -16.1 36.9 30.0 -13.2 4.7 1.5 
Blacks 19.3 31.0 27.6 3.4 20.3 15.6 
All races . 9.3 .,34.7 28.0 -11.4 5.3 2.2 
Data from Miller BA, Ries LAG, Hankey BF, Kosary CL, Harris A, Oevesa 55, 
Edwards BK, editors. SEER Cancer Statistics Review: 1973-1990. Bethesda, 
MO: National Cancer Institute, 1993. NIH Publication No. 93-2789 . 


























re 2. Changes in breast cancer incidence, 1973-1989, age-
adjusted rates. 
Figure 5. Changes in breast cancer mortality, 1973 -1989, age-
adjusted rates. 






Table 4. Changes in Breast Cancer Survival: 















Data from Miller BA. Ries LAG. Hankey BF, Kosary CL. Harris A, Devesa SS, 
Edwards BK, editors. SEER Cancer Statistics Review: 1973-1990. Bethesda, 
MD: National Cancer Institute, 1993. NIH Publication No. 93-2789, and the 
National Cancer Institute. 
Sondik et al., 1994. 
Fig. Ba - See next page • 
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Figure 4. Breast cancer incidence by stage at detection. age-adju~ted 
to 1970. 




Fig. Ba - A scanning electron micrograph of blood vessel systems 
before and after wounding. The picture on the left is before 
wounding, while the picture on the right is 60 hours after wounding. 
Note the extent of increased blood vessel formation, known as 
angiogenesis. While in wounding angiogenesis is used to speed ·the 
healing process, tumors release factors to promote angiogenesis 
so that a greater amount of nutrients are carried to the area of 
the tumor. This allows the tumor to grow beyond the normal parameters 
imposed by the body. (Alberts et al., 1989) 
control 
100 µm 





Fig. 9a - The double-helix structure of deoxyribonucleic acid, 
or DNA. The complementary base-pair interactions lie in the interior 
of the two strands. (Sherwood, 1993) 
(b) 




Fig. 9b - The polynucleotide aspect of DNA. Each nucleotide in a 
strand is composed of three parts: (1) a nitrogenous base, either 
adenine(A), guanine(G), cytosine(C), or thymine(T); (2) a five 
carbon sugar, or ribose; and (3) a phosphate group that forms a 
phosphodiester bond with the sugar of another nucleotide, which 
forms the chain. The bases are arranged to the interior of the 





Fig. 9c - Levels of organization of DNA. The DNA chain is wrapped 
around proteins known as histones, which then fold further and begin 
supercoiling into chromatin, the substance which makes up the 




Fig.9d - An electron micrograph of a chromosome. The centromere 
can be seen near the center of the structure. The shorter end i s 





Fig. 9e - Transfer of information from DNA to protein. The nucleotide 
sequence in DNA specifies the sequence of amino acids in a polypeptide. 
One strand of the normally two-stranded DNA chain is used to form a 
mRNA templated for the buildong of the polypeptide chain. Each three 
nucleotide sequence in the mRNA strand codes for one amino acid in the 
ploypeptide chain. The amino acid structure dictates the three-












Chromosome: Sq 12p 18q 17p 
Alteration: Loss Activation Loss Loss 




Other alterations • 
Normal Hyperprolif. Early Intermediate Late Carcinoma Meta,tasis 
epithelium epithelium adenoma adenoma adenoma 
Fig. 9f - Chromosomal loss in the progression of human cancer, 













Fig. 10 - Autoradiography exposure showing ~03s of heterozygosity 
(LOH) in the tumor DNA of a patient. DNA from -normal breast tissue 
is labeled B, while DNA from a breasi tumor is labeled T. Patient 
12 is heterozygous for the amplified allele. Notice intensity 
between the bottom two bands in the two samples is identical, while 
the top band of the tumor DNA is much lighter in intensity than the 
normal breast DNA. This is indicative of loss of a chromosomal 
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What p53 does. When 
the p53 protein is made, 
it turns on the gene for a 
21 kilodalton protein that 
blocks Cdk enzymes, 




Fig. 12 - Inhibition of cell division by 
the normal p53 gene. (Marx, 1993) 
Fig. I. Pauems of Al ar I I loci 
on chromosome 17 in individual 
infonna1ive rumors (left ) or at i 
five regions in groups of rumors : 
with similar Al pa!!em (right). 
The sizes of these groups are in -
dicared as percen1:1ges of the total 
sample number. The remaining 
1 • 21 'k- of the tumors not shown I 
(but 12 of which are shown to the 
left in the figure ) had various I 
combinations of Al on both 
chromosomal :inns . • = Al: 0 = 
no Al : ¢=not infonnarive or not 
an:liyzed: • = Al probably due 10 
increased THRA I copy number. 














Chromosome 1 7 and the location of BRCA1. 
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' ' , ' }D17S57' 
Fig. 1. Schematic map of human chromosome 
17. The pertinent region containing BRCA 1 is ex-
panded to indicate the relative positions of two 
previously identified genes, CA 125 (34 ) and 
RNU2 (45 ). 017S855 is located within BRCA 1 . 




Fig. 15 - Risks of cancer in BRCA1 carriers 
compared to non-carriers. (Ford et al., 1994) 
Sitt ( 9tll lCD codnl Camera Non-cantera Unknown Es11ma11c1 
(n • 464) (n • 2211 /. .. (n • 8421 RRln --- canltts Obs Exp Obs Exp Obs Exp - -Buccal cavity and pharynx 0 0·82 1 0·45 2 1·32 0·71 
(140-149) 
Oesophagus (150) 0 0·33 0 0·17 1 1HJ7 0·47 
Stomach (151) 1 0·76 0 0,37 1 1·39 1-11 
Colon (153) 7 2·22 2 1·30 10 3-28 3-30t 
Rectum (154) 1 1-15 1 0·64 0 1·77 0·53 
liver (155) 0 0·15 0 0·08 3 0·25 5·12 
Pancreas (157) 0 0·65 0 0·36 2 1·00 0·62 
Larynx (161) 1 0·36 1 0·17 0 0·60 1·58 
wnc (162) 2 4·32 0 2·22 5 7-03 0·57 
Bone (170) 0 dos 0 0·06 1 0·17 3·25 
Connectl'le tissue ( 171) 0 0·17 0 0·13 1 0·29 HO 
Melanoma (172) 1 . 0·81 0 0·57 1 . 1-10 1-18 
Cervix (180) 1 0·72 . 0 0·56 3 o-70 2·74 
Other UletUS (179, 181, 0 1·14 0 0·78 0 0·94 
182) 
Prostate (185) 7 1-61 0 0·80 s 3-56 2·95t 
Testis (186) ·~ 0 0·18 0 0·12 0 0·53 
Bladder ( 188) 0 1-16 1 0·60 1 2·09 0·24 
Kidney (189) 2 0·58 0 0·33 0 0·94 2·02 
B,ain (191,-192) 0 0·54 1 0·37 ' 0·94 2·08 Thyroia ~ r~~:. . , 0 0·38 0 0·30 1 0·43 0·93 
Hodgkin's disease (201) 0 0·26 0 0·22 0 0·55 
Other lymphoma (200. 202) 0 0·87 0 0·54 0 1·34 
Myetoma (203 ) 0 0·27 0 0·15 0 0·41 
Leukaemia (204-208) 0 0·66 0 0·44 0 1·23 
Other cancers 4 0·67 2 0·42 1 1·02 , -21• 
Unknown site ( 199) 4 0·90 0 0·51 4 1-42 3·97t 
All cancet1 uc,pt bleat, 31 21·76 9 12·66 47 34·87 1·44t 
Mtl', and non-melanoma 
""" •p< 0·05, tp <0·01. Obs • obse<ved, Exp• expected: RR • relative risk. 








Fig. 16 - Penetra~ce 
of BRCA1 at 
increasing age • 




Fig. 2. Estimates of penetrance. Each 
graph represents cumulative risk of de-
veloping breast or ovarian cancer as a 
function of age. Dashed line : log-normal 
fit to data from known and possible gene 
carriers in K2082; solid line: Kaplan-
~ ier step function estimate using data 
from K2082 known BRCA 1 carriers only; 
dotted line: penetrance estimates from 
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Fig. 17 - Four BRCA1-containing family pedigrees showing the 
severity of BRCA1 in the development of breast cancer. Squares 
represent males, circles represent females, darkened shapes 
represent those diagnosed with breast cancer, slashes indicate 
other types of cancer. (Hall et al., 1990) 
• Fig. 18 - Hematoxylin and Eosin (H&E) Staining Protocol 
for Tissue Sections on Glass Slides 
~ Chemical I.i..mil 
1 Xylene 10 min. 
2 Methanol 10 dips 
3 50% EtOH 10 dips 
4 Hematoxylin 4 min. 
5 HCl in Alcohol 10 dips 
6 70% EtOH 10 dips 
• 7 NH,OH in E tOH 30 sec . 8 95% EtOH 10 dips 
9 Eosin 25 dips 
10 Methanol 10 dips 
11 ·Methanol 10 dips 
12 Xylene 10 dips 
Apply 2 drops "Tissue Tek Coverslipping Resin" and cover slip . 
• 
•• Primer Design: Cig,G->T 
5'ACCGACTAGA------CGGTGGAATT 3' 
3'TGGCTGATCT GCCACCTTAA 5' 




------GCCTCCTTAA 5 1 ... 
Fig. 19 - Designing primers to anneal to certain regions of DNA 
in order to amplify a single region, or gene. Primers act as a 
starting point for DNA polymerase. (S. Volchenboum, 1994) 
5·-----3· 5·------3· S' ------3' 
3' --11-5' 3' -------s· 
Extend s·-----3' Denature 











5'-3' 3 S' 
3' 3' 5' 3' 5' 5 
Fig. 20 - The "thermal cycle" aspect of PCR. Each temperature 




3' 5· S' 3' 
3' 5' 
3' 
5' S' 3' 
5' 3' 
3' 5' After N rounds of 
3' 5' s· 3' PCR, there are N2 3' 5· 
S' 3' copies but only 
S' 3' 
3' 5' N+2 non-mutated 
3' s· S' 3' strands. 3' 3' s· 
5' s· 3' 
5' 3' 3' 5' 
3' S' s· 3' 
3' 5' 
Fig. 21 - The "chain ,_-:: .::ct ion" element of PCR. The number of 
amplified fragments grows 2.t a gr->om<?tric rate. (Volchenboum, 1994) 
• 
Fig. 22 Bands of normal and tumor DNA on a polyacrylamide 
DNA from normal breast tissue is marked with a N, while DNA 
gel. 
from 
tumor breast tissue is marked with a T. Patients that are 
heterozygous with no loss are marked H/N, while patients that are 
heterozygous with loss are marked H/L. Three different primers 
are shown: D6S265, D6S260, and D17S796 (p53 region). Patients 5 
and 16 are H/N, while patient 5 shows loss of the region amplified 




Primers for Prophylactic Mastectomy Study 
Primer Map Location Ref Allele Range HET 
017S849 17pter-p13.3 GOB 7/28/94-default 251-261 0.676 
017S796 17p13.3-p11.2 GOB 7/28/94-default 144-174 0.824 
017S786 17p13.3-p11.2 GOB 7/28/94-default 135-157 0.773 
017S804 17p13.3-p11.2 GOB 7/28/94-default 156-170 0.624 
017S799 17p13.3-p11.2 GOB 7/28/94-default 186-200 0.694 
017S783 17p11.2-q12 GOB 7/28/94-default 241-255 0.713 
017S788 17Q11 .2-qter GOB 7/28/94-default 186-19 0.703 
017S807 17q11.2-Qter GOB 7/28/94-default 114-138 0.862 
0175785 17q11.2-qter GOB 7/28/94-default 181-207 0.839 
017S784 17q11.2-qter GOB 7/28/94-default 226-238 0.786 
017S250/Mfd15 17q11.2-Q12 GOB 7/21/94 151-169 81 
013S171 13q12.3-Q13 GOB 7/21/94 227-241 0.727 
013S176 13q12.3-q31 GOB 7/21/94-default 211-227 0.802 
013S166 13q12.3-q31 GOB 7/21/94-default 115-125 0.757 
013S162 13q21.2-Q31 GOB 7/21/94 182-202 0.864 
013S158 13q32-q33 GOB 7/21/94 99-113 · 0.823 
013S159 13Q32 GOB 7/21/94 169-203 0.906 
SPN 16q11.2 GOB 7/22/94 145-185 0.96 
016S265/Mfd23 16q21 GOB 7/21/94 89-117 0.75 
016S413 16Q24.3 GOB 7/21/94 131-149 0.846 
0115902 11p15-p13 GOB 7/22/94 145-163 0.805 
INT-2 11q13 P(?lymeropoulos,M., e 161-177 0.846 
011S35 11Q22 GDB 7/22/94 152-162 0.88 
Mfd69/C030 11Q23.3 GOB 7/2.2/94 85-99 0.69 
06S286 6q16.3-Q21 GOB 7/22/94 206-232 0.792 
06S268 6q16.3-q21 GOB 7/22/94 86-100 0.754 
065308 6q16.3-q27 GCB 7/22/94 193-203 0.752 
06S264 6q25.2-q27 GOB 7/22/94 108-122 0.709 
03S1283 3p25-p24.2 GOB 7/22/94 150-160 0.71 
03S1289 3p21.2-p21.1 GOB 7/22/94 197-215 0.818 
03S1261 3p14-p12 GOB 7/22/94 185-217 0.853 
02S119 2p23-p15 GOB 7/22/94 214-232 0.81 
02S123 2p 197-227 0.773 
C08A 2p12 GOB 7/22/94 138-170 
01S243 1pter-p34 GOB 7/28/94-default 142-170 0.874 
01S233 1p36-p22 GOB 7/28/94-default 102-132 0.852 
01S162 1p36-p22 GOB 7/28/94-default 134 0.91 
Fig. 23 - A list of primers that have been or will be used in 
the prophylactic masectomy study at the Mayo Clinic. Four of 
the · primers, D17S796, D17S786, D17S250, and D17S807, were used 
in my portion of the project; (K. DeLacey, 1994) 
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Fi g. 24 - Resu l ts of the study. At left 
i s a g raphic showing the various markers 
on chromosome 17. The four primers used 
in the study are shown on the right, in 
t he r egions where they anneal. The sixteen 
patients us~d in the study are listed 
horizontally. The boxes above show the 
results of the loss of heterozygosity 
studies, according to the key at left. 






Loss of Heterozygosity Results 
p53 H/L HIN Homoz~gous I Indeterminate 
D17S796 I 
Patients 1, 11 7, 8 6, 12,15 12,3,4,5,9, 10, 13, 14, 15 
Percent Exe. Ind. 28.6 28.6 42.9 
Percent Exe. Hom. 50 50 I 
D17S786 
Patients 1,2,6,9, 11, 15 7 3,5,12,15 4,8,10,13,16 
Percent Exe. Ind. 54.5 36.4 9.1 




Patients 1,9 5,14,15 2,4,6,7, 11, 12 ' 3,8,10,13,16 
Percent Exe. Ind. 18.2 27.3 54.5 
Percent Exe. Hom. 40 60 
D17S807 
Patients 1,4,6,8,9, 12 2,7,14,15 3,5,11,16 10,13 
Percent Exe. Ind. 42.9 28.6 28.6 
Percent Exe. Hom. 60 40 - -
Total p53 0.571 0.429 
--
Total BRCA1 0.53~ 0.467 
Fig. 25 - Allelic scoring for the sixteen prophylactic masectomy 
patients in the study . H/ L corresponds to heterozygous/loss, 
H/N corresponds to heterozygous/no loss . The two tumo r suppressor 
genes studied and the corresponding primers are listed in the 
left-hand column. Patients f i tting into each category are listed 
by their study number. Percent loss of heterozygote individuals 
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